Unimedic announces new distribution agreement with Basilea for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries
Stockholm, September, 20th 2016 – Unimedic Pharma AB announced today that Unimedic has entered into a licence and distribution agreement with Basilea Pharmaceutica Ltd. (SIX: BSLN) for Basilea’s antifungal CRESEMBA® (isavuconazole) and antibiotic Zevtera® (ceftobiprole) in the Nordic countries, including Sweden, Denmark, Norway and Finland.